Nuvalent Inc
NUVLHealthcare|Biotechnology|USA
$123.90
+0.06 (+0.05%)
Tangible Book
$14.89
Upcoming Data Readouts (4)
Jan 2027
Est. completion
P1Locally Advanced Solid Tumor
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554n=200
Dec 2027
Est. completion
P1P2Locally Advanced Solid Tumor
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626n=840
Dec 2027
Est. completion
P1P2Locally Advanced Solid Tumor
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789n=359
Dec 2029
Est. completion
P3Non-small Cell Lung Cancer
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109n=450